Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models

Periostin (POSTN) interacts with multiple integrins to coordinate a variety of cellular processes, including epithelial-to-mesenchymal transition (EMT) and cell migration. In our previous study, anti-VEGF-A therapy was associated with resistance and EMT. This study sought to determine the role of POSTN in the resistance of glioma stem cells (GSC) to antiangiogenic therapy. In mouse xenograft models of human glioma, POSTN expression was associated with acquired resistance to anti-VEGF-A therapy and had a synergistic effect with bevacizumab in prolonging survival and decreasing tumor volume. Resistance to anti-VEGF-A therapy regulated by POSTN was associated with increased expression of TGFβ1 and hypoxia-inducible factor-1α (HIF1α) in GSCs. At the molecular level, POSTN regulated invasion and expression of EMT (caveolin-1) and angiogenesis-related genes (HIF1α and VEGF-A) through activation of STAT3. Moreover, recombinant POSTN increased GSC invasion. Collectively, our findings suggest that POSTN plays an important role in glioma invasion and resistance to antiangiogenic therapy. Mol Cancer Ther; 15(9); 2187–97. ©2016 AACR.

[1]  D. Born,et al.  Periostin is a novel therapeutic target that predicts and regulates glioma malignancy. , 2015, Neuro-oncology.

[2]  F. Boccardo,et al.  Periostin: a novel prognostic and therapeutic target for genitourinary cancer? , 2014, Clinical genitourinary cancer.

[3]  P. Wen,et al.  Current status of antiangiogenic therapies for glioblastomas , 2014, Expert opinion on investigational drugs.

[4]  G. Fuller,et al.  Neutrophils Promote the Malignant Glioma Phenotype through S100A4 , 2013, Clinical Cancer Research.

[5]  K. Moriyama,et al.  Periostin inhibits hypoxia-induced apoptosis in human periodontal ligament cells via TGF-β signaling. , 2013, Biochemical and biophysical research communications.

[6]  J. D. de Groot,et al.  Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition , 2013, Clinical Cancer Research.

[7]  Chuanlu Jiang,et al.  Stromal protein periostin identified as a progression associated and prognostic biomarker in glioma via inducing an invasive and proliferative phenotype. , 2013, International journal of oncology.

[8]  I. Verma,et al.  Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme , 2013, Journal of Molecular Medicine.

[9]  J. Heymach,et al.  Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. , 2012, Neuro-oncology.

[10]  G. Fuller,et al.  Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma , 2012, Oncotarget.

[11]  T. Shibata,et al.  Periostin Directly and Indirectly Promotes Tumor Lymphangiogenesis of Head and Neck Cancer , 2012, PloS one.

[12]  Hong Peng,et al.  Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.

[13]  H. Inoue,et al.  Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells. , 2011, International journal of oncology.

[14]  Mary J. C. Hendrix,et al.  ErbB/EGF Signaling and EMT in Mammary Development and Breast Cancer , 2010, Journal of Mammary Gland Biology and Neoplasia.

[15]  S. Hoersch,et al.  Periostin shows increased evolutionary plasticity in its alternatively spliced region , 2010, BMC Evolutionary Biology.

[16]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[17]  R. Kerbel,et al.  Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy , 2009, Clinical Cancer Research.

[18]  J. D. de Groot,et al.  Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[19]  J. Olzmann,et al.  Corneal Dystrophy-associated R124H Mutation Disrupts TGFBI Interaction with Periostin and Causes Mislocalization to the Lysosome* , 2009, The Journal of Biological Chemistry.

[20]  R. Markwald,et al.  Periostin promotes a fibroblastic lineage pathway in atrioventricular valve progenitor cells , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[21]  J. Tonn,et al.  Expression of Integrin αvβ3 in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature , 2008, Brain pathology.

[22]  M. Koch,et al.  Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors , 2008, Clinical Cancer Research.

[23]  R. Markwald,et al.  Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. , 2007, Developmental biology.

[24]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[25]  R. Shao,et al.  Transduction of a Mesenchyme-specific Gene Periostin into 293T Cells Induces Cell Invasive Activity through Epithelial-Mesenchymal Transformation* , 2006, Journal of Biological Chemistry.

[26]  S. Toda,et al.  Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. , 2006, The Journal of allergy and clinical immunology.

[27]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[28]  R. Cheung,et al.  Nitric oxide down‐regulates caveolin‐1 expression in rat brains during focal cerebral ischemia and reperfusion injury , 2006, Journal of neurochemistry.

[29]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[30]  S. Prime,et al.  Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF‐β1 involves MAPK, Smad and AP‐1 signalling pathways , 2005, Journal of cellular biochemistry.

[31]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[32]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[33]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[34]  E. Hay,et al.  DIRECT EVIDENCE FOR A ROLE OF β‐CATENIN/LEF‐1 SIGNALING PATHWAY IN INDUCTION OF EMT , 2002, Cell biology international.

[35]  Seng H. Cheng,et al.  Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. , 2002, Biochemical and biophysical research communications.

[36]  S. Goerdt,et al.  Stabilin-1 and −2 constitute a novel family of fasciclin-like hyaluronan receptor homologues , 2002 .

[37]  Sally Temple,et al.  The development of neural stem cells , 2001, Nature.

[38]  M. Weller,et al.  Processing of Immunosuppressive Pro-TGF-β1,2 by Human Glioblastoma Cells Involves Cytoplasmic and Secreted Furin-Like Proteases1 , 2001, The Journal of Immunology.

[39]  In‐San Kim,et al.  Identification of Motifs for Cell Adhesion within the Repeated Domains of Transforming Growth Factor-β-induced Gene,βig-h3 * , 2000, The Journal of Biological Chemistry.

[40]  Lynda F. Bonewald,et al.  Identification and Characterization of a Novel Protein, Periostin, with Restricted Expression to Periosteum and Periodontal Ligament and Increased Expression by Transforming Growth Factor β , 1999 .

[41]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[42]  Takeshi Kawamoto,et al.  Characterization of a cartilage-derived 66-kDa protein (RGD-CAP/beta ig-h3) that binds to collagen. , 1997, Biochimica et biophysica acta.

[43]  T. Nose,et al.  Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.

[44]  P. Black,et al.  Microvessel density is a prognostic indicator for patients with astroglial brain tumors , 1996, Cancer.

[45]  R. Kikuno,et al.  Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. , 1993, The Biochemical journal.

[46]  Shigeaki Kobayashi,et al.  Detection of Active Form of Transforming Growth Factor‐β in Cerebrospinal Fluid of Patients with Glioma , 1993, Japanese journal of cancer research : Gann.

[47]  T. Ichikawa,et al.  Integrin inhibitor suppresses bevacizumab-induced glioma invasion , 2014 .

[48]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[49]  E. Hay,et al.  Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. , 2005, Cells, tissues, organs.

[50]  S. Goerdt,et al.  Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues. , 2002, The Biochemical journal.

[51]  T. Yoneda,et al.  Patterns of gene expression associated with BMP-2-induced osteoblast and adipocyte differentiation of mesenchymal progenitor cell 3T3-F442A , 2000, Journal of Bone and Mineral Metabolism.

[52]  K. Horiuchi,et al.  Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.